Abstract
Molecular testing of patients with advanced non-small cell lung carcinoma (NSCLC) for actionable genomic alterations (GA) is recommended. We aimed to assess the characteristics, molecular profile and clinical outcomes of patients with NSCLC assessed by next-generation sequencing (NGS) within routine clinical practice at our center.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
